Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Rivastigmine TDS
Amarin Technologies S.A. Argentina flag Argentina
Abstract ID:
Transdermal system destined to the treatment of dementia....
Contact Sergio Lucero
Participants
You
Email me a copy of this message
MECHANISM OF ACTION
The precise mode of action is unknown. It is thought to exert its therapeutic effect by enhancing cholinergic function.

Rivastigmine TDS is indicated for the treatment of dementia of the Alzheimer's type, and dementia associated with Parkinson Disease.

Comparative bioavailability of Rivastigmine TDS vs Exelon® patch has been evaluated in two Phase I clinical studies, obtaining similar PK profiles.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
AMARIN is seeking to license this product for USA, Europe and RoW.
FEATURED
Last Updated Aug 2016
Technology Type THERAPEUTIC
Phase of Development CLINICAL TRIALS
CORPORATION